#408: Opioid Therapy Follow-up Evaluation

Quality ID

408

High Priority Measure

Yes

Specifications

Registry

Measure Type

Process

Specialty

Family Medicine Geriatrics Internal Medicine Neurology Orthopedic Surgery Physical Medicine

Measure Description

All patients 18 and older prescribed opiates for longer than six weeks duration who had a follow-up evaluation conducted at least every three months during Opioid Therapy documented in the medical record

 

Instructions

This measure is to be submitted a minimum of once per performance period for all patients being prescribed opioids for duration longer than six weeks during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

NOTE: Include only patients that have 6 weeks opioid use through September 30 of the performance period. This will allow the follow-up evaluation of at least 90 days after opioid therapy within the performance period.

Measure Submission Type

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

 

Denominator

All patients 18 and older prescribed opiates for longer than six weeks duration

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

WITHOUT

Telehealth Modifier: GQ, GT, 95, POS 02

AND

Patients prescribed opiates for longer than six weeks: G9561

AND NOT

DENOMINATOR EXCLUSION:

Patients who were in hospice at any time during the performance period: M1022

 

Numerator

Patients who had a follow-up evaluation conducted at least every three months during opioid therapy

Definition:

Follow-Up Evaluation – periodic MIPS eligible clinician encounters to reassess patients on Continuous Opioid Therapy (COT) as warranted by changing circumstances surrounding the patient. Monitoring should include:

• Documentation of pain intensity and level of functioning
• Assessments of progress toward achieving therapeutic goals
• Presence of adverse events
• Adherence to prescribed therapies

Numerator Options:

Performance Met: Patients who had a follow-up evaluation conducted at least every three months during opioid therapy (G9562)

OR

Performance Not Met: Patients who did not have a follow-up evaluation conducted at least every three months during opioid therapy (G9563)

Register with MDinteractive